NHI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
National Health Investors Inc (NHI) is not a strong buy for a beginner investor with a long-term horizon at the moment. The technical indicators are neutral, and the financial performance shows declining profitability despite revenue growth. Analyst ratings are mixed, with no strong upward momentum in price targets. The lack of significant positive catalysts and trading signals further supports a hold recommendation.
The MACD histogram is negative (-0.222) and contracting, indicating no strong bullish momentum. RSI is neutral at 53.913, and moving averages are converging, suggesting indecision in price direction. Key support and resistance levels indicate limited upside potential in the short term.
Revenue increased by 23.40% YoY in Q4 2025, and analysts expect favorable fundamentals to improve occupancy rates in the senior housing portfolio.
Analysts have mixed ratings, with some downgrades and limited upward revisions in price targets. No recent news or significant trading activity from insiders, hedge funds, or Congress.
In Q4 2025, revenue grew significantly by 23.40% YoY to $105.82 million. However, net income decreased by 11.80% YoY to $38.11 million, EPS dropped by 15.79% to $0.8, and gross margin fell by 10.35% to 75.43%.
Analysts are mixed. Wells Fargo raised the price target to $86 but maintained an Equal Weight rating. Truist raised the price target to $92 with a Buy rating, while Deutsche Bank downgraded the stock to Hold with an $85 price target. Cantor Fitzgerald lowered the price target to $85 but maintained an Overweight rating.
